NCT06563999 2026-04-21
NUMER
Sun Yat-sen University
Phase 2 Recruiting
Clinical Trials
6 trialsNCT05751018 2025-12-02
Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT06185400 2023-12-29
RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT05745740 2023-11-27
A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation
RemeGen Co., Ltd.
Phase 1/2 Unknown
NCT04063462 2019-08-21
Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT02535507 2015-08-28
Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung Cancer
Tongji University
Phase 2 Unknown